Monroe Biomedical Research (MBR), a leading clinical research site dedicated to advancing patient-centered trials, is proud to highlight its designation as a Global Impact Partner with the Society for Clinical Research Sites (SCRS).
SCRS announced MBR as a Global Impact Partner on July 22, 2025. The milestone underscores MBR’s commitment to supporting clinical trial site success, strengthening collaboration with sponsors, and promoting innovation across the global research community.
Expanding Our Voice in Clinical Research
SCRS is a global advocacy organization dedicated to representing and supporting clinical research sites. As a Global Impact Partner, Monroe Biomedical Research joins a network of organizations working together to drive positive change in site sustainability, efficiency, and patient engagement.
“Becoming a Global Impact Partner with SCRS reflects our commitment to helping improve clinical research. We believe strong partnerships between sites, sponsors, and patients are the foundation for meaningful progress in advancing medicine.” — Suvi Gross, CEO and Co-Founder of Monroe Biomedical Research
A Commitment to Patients and Communities
For over a decade, Monroe Biomedical Research has been recognized for its ability to deliver rapid, high-quality clinical trial results while prioritizing the patient experience. By aligning with SCRS, MBR will continue to advocate for the site voice while ensuring patients remain at the center of every trial.
“Our mission has always been clear: put patients first. Partnering with SCRS gives us a platform to amplify that mission on a global scale.” — Suvi Gross
About SCRS
The Society for Clinical Research Sites (SCRS) is the leading trade organization dedicated to representing the voice of clinical research sites around the world. Through advocacy, education, and community, SCRS provides sites with the resources and partnerships needed to succeed in an increasingly complex research environment.
About Monroe Biomedical Research
Founded in 2014, Monroe Biomedical Research specializes in outpatient clinical trials for chronic and acute conditions such as COPD, asthma, diabetes, heart failure, and more. Recognized for its strong enrollment performance, compliance with Good Clinical Practice (GCP), and patient-first approach, MBR partners with sponsors to bring innovative therapies to market through safe, ethical, and efficient study execution.
